MedTrace Logo

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

NCT00493883 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2015-05-13

No results posted yet for this study

Summary

The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity.

The study has the following objectives:

* Provide supervised access to treatment with TheraSphere to eligible patients with primary and metastatic cancer to the liver.
* Evaluate patient experience and toxicities associated with TheraSphere treatment
* Evaluate predisposing factors that may influence results and toxicity

Conditions

  • Carcinoma, Hepatocellular
  • Liver Neoplasms

Interventions

DEVICE

yttrium Y 90 microspheres (TheraSphere®)

Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver

Sponsors & Collaborators

  • Southwestern Regional Medical Center

    lead OTHER

Principal Investigators

  • James P Flynn, MD · Southwestern Regional Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493883 on ClinicalTrials.gov